食管癌靶向免疫治疗.pptxVIP

食管癌靶向/免疫治疗  (ESCC) has a high prevalence in East Asia, eastern and southern Africa, and southern Europe. Esophageal squamous cell carcinoma  has a high prevalence in East Asia, eastern and southern Africa, and southern Europe. However, the incidence rate of ESCC is low in North America and other parts of Europe.  01 靶向篇 NCCN 2020 V4 HER2阳性的食管癌腺癌患者，曲妥珠单抗+化疗 为一线推荐治疗方案 推荐拉罗替尼或恩曲替尼治疗NTRK融合食管癌患者 02 免疫篇 NCCN 2020 V4 CSCO 2020 早期 晚期/转移 辅助 一线治疗 二线治疗 三线治疗 Nivo vs Doc/TAX ATTRACTIONⅢ期(全球) Nivo vs 安慰剂 CM-57